类风湿关节炎患者接受甲氨蝶呤治疗至少6个月后的尿甲氨蝶呤剂量测定:一种潜在的依从性标志物
在兰斯大学医院开展的横断面研究中,纳入84例接受甲氨蝶呤治疗超过6个月的类风湿关节炎患者,采用尿甲氨蝶呤剂量测定(METU)评估依从性并与间接依从性测量方法比较。METU显示91.7%患者依从,而药物持有率(MPR)和风湿病依从性问卷(CQR)报告的依从比例分别为69.5%和61.9%,间接测量未能反映真实依从性。
要点
- 84例类风湿关节炎患者中,METU判定91.7%依从,MPR和CQR分别为69.5%和61.9%。
- 皮下甲氨蝶呤使用者中MPR与METU差异未达统计学显著(p=0.059)。
- 非依从患者压痛关节数和C反应蛋白值更高(p<0.05)。
核心结论
- 这是首个使用尿甲氨蝶呤剂量测定评估类风湿关节炎患者甲氨蝶呤依从性的最大规模研究,发现间接依从性测量未能反映真实依从性。
- 作者认为,可在新研究中针对治疗反应无法解释的类风湿关节炎患者进行METU,在升级治疗策略前加以考虑。
研究设计与样本
- 在兰斯大学医院开展的横断面研究,纳入84例年龄超过18岁、接受甲氨蝶呤治疗超过6个月的类风湿关节炎患者。
- 患者完成人口学、临床和心理问卷及依从性测量技术(风湿病依从性问卷CQR和药物持有率MPR),并采集尿液样本测定甲氨蝶呤。
- 通过甲氨蝶呤不耐受严重程度评分评估耐受性信息。
主要发现
- 84例患者中26例使用口服甲氨蝶呤,58例使用皮下甲氨蝶呤;73%为女性,平均年龄61.5岁,甲氨蝶呤平均剂量15 mg/周,61.9%接受生物改善病情抗风湿药治疗。
- 77例(91.7%)根据METU依从治疗,而MPR和CQR报告的依从比例较低,分别为69.5%和61.9%。
- 皮下甲氨蝶呤使用者中MPR与METU差异未达统计学显著(p=0.059)。
- 非依从患者压痛关节数和C反应蛋白值更高(p<0.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Non-adherence to rheumatoid arthritis (RA) treatments must be identified. A methotrexate (MTX) urinary dosage (METU) was recently developed. The aim of our study was to assess adherence to MTX in RA using METU in real-life conditions and to compare it with indirect adherence measurement technics. METHODS: We performed a cross-sectional study at Reims University Hospital. We included over 18-year-old patients with RA treated by MTX for more than 6 months. Patients were invited to complete demographic, clinical and psychological questionnaires and adherence measurement technics (Compliance Questionnaire of Rheumatology (CQR) and Medication Possession Ratio (MPR)). A urinary sample was collected to measure MTX and information about tolerance was evaluated through Methotrexate Intolerance Severity Score. RESULTS: 84 patients were included, 26 using oral MTX, 58 subcutaneous (SC) MTX. Among them, 73% were female, mean age was 61.5 years, MTX mean dose was 15 mg/week and 61.9% were treated by biological DMARDs (Disease Modifying Antirheumatic Drugs). 77 patients (91.7%) were adherent to treatment according to METU, whereas MPR and CQR reported less adherence (69.5% and 61.9%, respectively). MPR and METU were not significantly different in SC MTX users (p=0.059). Non-adherent patients had a higher number of tender joints and C reactive protein value (p<0.05). CONCLUSION: This is the first largest study evaluating MTX adherence in patients with RA using a urinary dosage. We identified that indirect adherence measurements did not reflect real-life adherence. It would be appreciable to realise METU, in a new study, in patients with RA with unexplained response to treatment, to consider it before escalating therapeutic strategy.
引用
- Théate N, Geoffroy M, Kanagaratnam L, et al. Urinary methotrexate dosage in rheumatoid arthritis, in patients treated for at least 6 months: a potential marker of adherence. RMD Open. 2024. PMID: 38772677. doi:10.1136/rmdopen-2023-004024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。